20 December 2007 – Actelion Ltd (SWX: ATLN) announced that the company has initiated the comprehensive Phase III program RESTORA (REstore physiological Sleep with The Orexin Receptor Antagonist Almorexant) with its first-in-class orexin receptor antagonist, almorexant...RESTORA 1 is expected to confirm the effects of almorexant on sleep induction and sleep maintenance that were previously observed. This study is also expected to provide additional information on sleep architecture and sleep quality, thereby providing further insight into the role of almorexant in restoring normal physiological sleep... Actelion's Press Release -
Thursday, December 27, 2007
Actelion, Phase III program RESTORA (REstore physiological Sleep with The Orexin Receptor Antagonist Almorexant)
20 December 2007 – Actelion Ltd (SWX: ATLN) announced that the company has initiated the comprehensive Phase III program RESTORA (REstore physiological Sleep with The Orexin Receptor Antagonist Almorexant) with its first-in-class orexin receptor antagonist, almorexant...RESTORA 1 is expected to confirm the effects of almorexant on sleep induction and sleep maintenance that were previously observed. This study is also expected to provide additional information on sleep architecture and sleep quality, thereby providing further insight into the role of almorexant in restoring normal physiological sleep... Actelion's Press Release -
